Filing Flows › Supernus Pharmaceuticals (SUPN) › Q2 2025
Supernus Pharmaceuticals (SUPN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Supernus Pharmaceuticals (SUPN) reported revenue of $165M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +10% from the quarter before. Operating margin was 7.3%, net earnings $22.5M (13.6% of revenue).
Supernus Pharmaceuticals, Q2 2025: revenue $165M (-2% year over year), operating margin 7.3%, net earnings $22.5M, operating cash flow $58.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $165M | +10% | -2% |
| Operating profit | $12.1M | — | -46% |
| Net earnings | $22.5M | — | +13% |
| Operating cash flow | $58.5M | +91% | +64% |
| Free cash flow | $58.1M | +92% | +63% |
What changed
Revenue was $165.5M in Q2 2025, down 2% year over year and up 10% from the previous quarter. Qelbree was the largest line at 47% of revenue. Oxtellar XR lost $17.9M year over year (down 61%), 623% of the total change.
Operating profit was $12.1M, a 7.3% margin (down 6.1 points year over year). Total costs grew 5% against a revenue fall of 2%. The fastest-growing cost line was Other operating costs (+32%). Net earnings were $22.5M, up 13% year over year. The effective tax rate was -35.0%. Non-operating items added $4.5M, 27% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $58.5M (up 64% year over year), 260% of net earnings. Non-cash charges added back $21.4M of depreciation and amortization and $7.5M of share-based compensation. Working capital and other items added $7.2M. Capital expenditures of $455K left free cash flow of $58.1M.
Questions
What was Supernus Pharmaceuticals' revenue in the second quarter 2025?
Supernus Pharmaceuticals (SUPN) reported revenue of $165M for the second quarter 2025 (Q2 2025), -2% from a year earlier and +10% from the quarter before.
Was Supernus Pharmaceuticals profitable in the second quarter 2025?
Operating profit was $12.1M (7.3% of revenue) and net earnings $22.5M.